The edition · Obstetrics & Gynaecology
PCOS gets a new name, and a sharper list of risks to track
Plus what proteinuria severity says about long-term kidney risk after pre-eclampsia, a small gestational-hypertension signal with the RSV vaccine, and natural-estrogen pills moving towards first line.
The edition in brief
Today's obstetrics and gynaecology edition leads on a change of frame rather than a trial. Following an international consensus endorsed by 56 organisations, polycystic ovary syndrome is renamed polyendocrine metabolic ovarian syndrome; the diagnostic criteria are unchanged, but the new name reframes a lifelong endocrine-metabolic condition that is underdiagnosed and under-documented, and that raises obstetric risk. A Danish cohort of 286,078 pregnancies shows pre-eclampsia carries higher 10-year risks of hypertension, chronic kidney disease and cardiovascular disease, with kidney risk rising with heavier proteinuria — 5.1% versus 1.2% at 10 years — a basis for stratifying follow-up. A meta-analysis of 148,267 pregnancies finds maternal RSVpreF vaccination linked to a small rise in hypertensive disorders (risk ratio 1.08), confined to gestational hypertension and driven by observational data; the infant benefit stands and the vaccine should still be offered. A GRADE-rated synthesis finds doula support probably lowers preterm birth and caesarean rates, though most outcomes are low-certainty. A clinic pearl reaffirms structured postpartum cardiometabolic follow-up after any hypertensive pregnancy. The practice-changer: a review argues natural-estrogen combined oral contraceptives, with their better venous thromboembolism profile, should move to first line for new starts.
Polycystic ovary syndrome renamed polyendocrine metabolic ovarian syndrome
Record the diagnosis under the new name and manage it as a lifelong endocrine-metabolic condition, documenting it as an obstetric risk modifier at booking.
Heavier proteinuria in pre-eclampsia marks higher later kidney risk
After pre-eclampsia, use the recorded proteinuria severity to decide how closely to watch long-term renal and blood-pressure health.
Maternal RSV vaccine and a small gestational-hypertension signal
Keep offering RSVpreF in pregnancy and include the small gestational-hypertension signal in shared decision-making rather than withholding it.
Doula support linked to fewer preterm and caesarean births
Where doula support is available, consider facilitating it, particularly for women facing care disparities, while setting realistic expectations about the evidence.
Close the loop after a hypertensive pregnancy
Before discharge, arrange a postpartum blood-pressure and cardiometabolic review for every woman who had a hypertensive disorder of pregnancy.
Natural-estrogen combined pills proposed as first line for new starts
For a woman starting combined oral contraception, consider a natural-estrogen formulation to lower venous thromboembolism risk while keeping efficacy.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free